Why AC Immune SA (ACIU) stock had a BAD Friday?

Related Topics

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

AC Immune SA (ACIU) shares plunged 5.26% in after-hours on Friday, June 25, 2021, and closed the week at $7.75 per share. Earlier, in the morning session, ACIU’s stock lost 2.27% to close Friday’s session at $8.18 per share. ACIU shares have risen 20.12% over the last 12 months, and they have moved up 3.15% in the past week. Over the past three months, the stock has gained 7.21%, while over the past six months, it has declined 48.73%.

Let’s see what’s happening recently with ACIU?

Annual General Meeting

On June 25, 2021, AC Immune held its Annual General Meeting per Swiss law. Shareholders cast their votes through the independent proxy appointed by the shareholders.

Douglas Williams, Martin Velasco, Peter Bollmann, Alan Colowick, Tom Graney, Carl June, Werner Lanthaler, Andrea Pfeifer, and Roy Twyman were re-elected on the Board of Directors by the shareholders. Douglas Williams and Martin Velasco will continue to serve as Chairman and Vice-Chairman of the Board, respectively.

Update on Alzheimer’s disease Vaccine candidates 

On June 02, 2021, AC Immune SA provided key clinical and preclinical updates for its SupraAntigen®-derived liposomal vaccine candidates, which are designed to convey active, long-lasting immunization against pathological forms of amyloid-beta (Abeta).

AC Immune is completing a Phase 2 study of its first clinical candidate, ACI-24, in people with mild Alzheimer’s disease (AD), and is also advancing an optimized ACI-24 formulation, which demonstrates enhanced and sustained immunogenicity in non-human primate studies, particularly against key pathological forms of Abeta such as oligomeric and pyroglutamate Abeta.

Phase 1b/2a clinical trial expansion of anti-phosphorylated-Tau (pTau) vaccine candidate

On May 17, 2021, AC Immune SA and its strategic partner Janssen Pharmaceuticals, Inc. expanded the ongoing Phase 1b/2a clinical trial of the Companies’ first-in-class anti-phosphorylated-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer’s disease (AD).

Recent financial results

On April 28, 2021, AC Immune SA announced its financial results for the quarter ended March 31, 2021.

Q1 2021 financial highlights

  • There was no contract revenue for Q1 2021 compared to CHF 12.3 million in Q1 2020.
  • The company spent CHF 13.3 million in R&D expenses compared to CHF 2 million for Q1 2020.
  • General and administrative expenses were CHF 4.3 million for Q1 2021 compared to CHF 4.5 million for Q1 2020.
  • Net loss for the reported quarter was CHF 16.7 million compared with a net loss of CHF 7.7 million for the comparable period in 2020.
  • As of March 31, 2021, the company had a total cash balance of CHF 216.1 million, composed of CHF 151.1 million in cash and cash equivalents and CHF 65 million in short-term financial assets.


As of this writing, there was no news or development which could be linked with its poor performance on Friday. so we are unable to predict how ACIU stock will perform in the coming days.

Leave a Comment

Your email address will not be published. Required fields are marked *

Latest Posts



Download Free eBook For


100% free. stop anytime no spam